Efficacy of zoledronic acid and pamidronate in breast cancer patients: A comparative analysis of randomized phase III trials

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 6 SUPPL. 1, 2002, Pages

  Coleman, Robert E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Bisphosphonate; Bone metastases; Breast cancer; Skeletal related events; Zoledronic acid

Indexed keywords

PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ANALGESIA; BONE LESION; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; INFUSION; MAJOR CLINICAL STUDY; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL ANALYSIS;

BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; DIPHOSPHONATES; HUMANS; IMIDAZOLES; RANDOMIZED CONTROLLED TRIALS;

EID: 0036898482     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200212001-00005     Document Type: Conference Paper

References (22)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Coleman RE, Rubens RD. Bone metastases and breast cancer. Cancer Treat Rev 1985;12:251-70.
3. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
4. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lyric bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996:335:1785-91.
5. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. For the Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038-44.
6. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-54.
7. Turner SL, Gruenewald S, Spry N, et al. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer 2001;84:297-302.
8. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16:593-602.
9. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:488-93.
10. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-90.
11. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001;7:377-87.
12. Rosen L, Gordon DH, Dugan W Jr, et al. Zoledronic acid (4 mg) is more effective than pamidronate (90 mg) for treating bone metastases in breast cancer patients with at least one osteolytic lesion [Abstract 629]. Presented at the European Society of Medical Oncology Congress; Oct 18-22, 2002; Nice, France.
13. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000;18:1378-91.
14. Demers LM, Costa L, Chinchilli VM, et al. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995;41:1489-94.
15. Vinholes J, Coleman R, Lacombe D, et al. Assessment of bone response to systemic therapy in an EORTC trial: Preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer. Br J Cancer 1999;80:221-8.
16. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-51.
17. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study [published erratum appears in Cancer 2001;91:1956]. Cancer 2001;91:1191-200.
18. Berenson JR, Vescio R, Henick K, et al. A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 2001;91:144-54.
19. Binkley N, Kimmel D, Bruner J, et al. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res 1998;13:1775-82.
20. Bare S, Kimmel D, Binkley N, et al. Zoledronate (CGP 42,446) suppresses turnover without affecting mineralization in cancellous bone of the ovariectomized non-human primate [Abstract S482]. J Bone Miner Res 1997;12(suppl 1):S473.
21. Lipton A, Small E, Saad F, et al. The new bisphosphonate, ZOMETA® (zoledronic acid) decreases skeletal complications in both osteolytic and osteoblastic lesions: A comparison to pamidronate. Cancer Invest [in press].
22. Coleman RE, Rosen L, Gordon D, et al. Zoledronic acid (4 mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90 mg) in patients with breast cancer and bone metastasis [Abstract 355]. To be presented at: 25th Annual San Antonio Breast Cancer Symposium; Dec 11-14, 2002, San Antonio, Texas.